Pseudarthrosis

Published results showed patients who received bone morphogenetic protein during single-level anterior lumbar interbody fusion had increased risk for symptomatic pseudarthrosis with no improvement in revision rates.

The FDA cleared an investigational new drug application for NVD-003, a stem cell therapy for treatment of children with congenital pseudarthrosis of the tibia, according to the agent’s manufacturer.